Outcomes of treatment of juvenile idiopathic arthritis related uveitis with TNF-alpha inhibitors

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


The aim of the study was to evaluate the efficacy of two anti-TNF-alpha biological agents: Adalimumab (humanized monoclonal anti-TNF-alpha antibody) and Infliximab (chimeric monoclonal antibody that binds both circulating and membrane-bound TNF-alpha receptors) in treatment of Juvenile Idiopathic Arthritis related uveitis. 37 children (73 % girls) with uveitis associated with aggressive forms of JIA who failed Methotrexate and topical treatment; Methotrexate and other immunosuppressive agents and systemic corticosteroids were included in the study. The age of patients at the beginning of biological therapies ranged 5-17 years. In ADA group the remission was observed in 61 % of cases, in 18 % we saw the reduction of flare-ups and in 14 % of children we registered exacerbation of the disease which was caused in most cases by discontinuation of non-biological drug. In INF group we observed remission in 78 % of the cases, no improvement in 22 %. The speed of remission in JIA associated uveitis treated with ADA and INF depended on the severity of uveitis, the time between the beginning of the disease and administration of immunosuppressive therapy. Early administration of anti-TNF-alpha agents, when there is no results from standard immunosuppressive therapy, allowed us to achieve remission in a shorter period of time and also allowed as to decrease the severity of complications of uveitis, as well as reduce the side effects of immunosuppressive therapy, especially of corticosteroids. This study needs to be continued to enroll more patients and to increase the follow-up time to evaluate the long-term efficacy and safety of anti-TNF-alpha agents in JIA associated uveitis.

Full Text

Restricted Access

About the authors

Ekaterina Vladimirovna Gaidar

Saint Petersburg State Pediatric Medical University

Email: gaidare85@gmail.com
MD, Research Fellow, Chair of Hospital Pediatrics

Mikhail Mikhaylovich Kostik

Saint Petersburg State Pediatric Medical University

Email: mikhail.kostik@gmail.com
MD, PhD, Associate Professor, Chair of Hospital Pediatrics

Ludmila Stepanovna Snegireva

Saint Petersburg State Pediatric Medical University

Email: l.s.snegireva@mail.ru
MD, Department of Pediatrics N 3

Margarita Fedorovna Dubko

Saint Petersburg State Pediatric Medical University

Email: andrq@rambler.ru
MD, PhD, Associate Professor, Chair of Hospital Pediatrics

Vera Vasilyevna Masalova

Saint Petersburg State Pediatric Medical University

Email: masalova.vera@gmail.com
MD, Research Fellow, Chair of Hospital Pediatrics

Elena Dmitrievna Serogodskaya

Saint Petersburg State Pediatric Medical University

Email: edserogod@yandex.ru
MD, PhD, Associate Professor, Chair of Ophthalmology

Aida Sirradzidinovna Macijevska

Dr. Solomatina EYE Surgery Center

Email: aidajed@inbox.lv
ophthalmologist

Alla Hynes

Eye Care Physicians and Surgeons

Email: rozalat@hotmail.com
ophthalmologist

References

  1. Moshetova L. K., Ermakova N. A. Oftal’mologiya: natsional’noe rukovodstvo [Ophthalmology: the national guide]. M.: GEOTAR-Media; 2013.
  2. Acevedo S., Quinones K., Rao V., et al. Cataract surgery in children with juvenile idiopathic arthritis associated uveitis. Int Ophthalmol Clin. 2008; 48 (2): 1-7.
  3. Boone M. I., Moore T. L., Cruz O. A. Screening for uveitis in juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus. 1998; 35 (1): 41-3.
  4. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. Textbook of Pediatric Rheumatology. 6th edition. Saunders; 2010.
  5. Ceisler E. J., Foster C. S. Juvenile rheumatoid arthritis and uveitis: minimizing the blinding complications. Int Ophthalmol Clin. 1996; 36 (1): 91-107.
  6. Gallagher K. T., Bernstein B. Juvenile rheumatoid arthritis. Curr Opin Rheumatol. 1999; 11 (5): 372-76.
  7. Hoeve M., Kalinina Ayuso V., Schalij-Delfos N. E., Los L. I., Rothova A., de Boer J. H. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol. 2012; 96 (6): 852-56.
  8. Holland G. N. Intraocular lens implantation in patients with juvenile rheumatoid arthritis-associated uveitis: an unresolved management issue. Am J Ophthalmol. 1996; 122 (2): 255-57.
  9. Imrie F. R., Dick A. D. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007; 18 (6): 481-86.
  10. Kesen M. R., Setlur V., Goldstein D. A. Juvenile idiopathic arthritis-related uveitis. Int Ophthalmol Clin. 2008; 48 (3): 21-38.
  11. Kotaniemi K., Kaipiainen-Seppanen O., Savolainen A., et al. A population-based study on uveitis in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 1999; 17 (1): 119-22.
  12. Päivönsalo-Hietanen T., Tuominen J., Saari K. M. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. Feb 2000; 78 (1): 84-8.
  13. Qian Y., Acharya N. R. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2010; 21 (6): 468-72.
  14. Shetty A. K., Zganjar B. E., Ellis G. S. Jr., et al. Low-dose methotrexate in the treatment of associated chronic anterior uveitis. Rheumatology (Oxford). 2008; 47 (3): 339-44.
  15. Tynjala P., Kotaniemi K., Lindahl P., et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008; 47 (3): 339-44.
  16. Yu E. N., Meniconi M. E., Tufail F., et al. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm. 2005; 13 (5): 353-60.

Statistics

Views

Abstract - 446

PDF (Russian) - 362

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2014 Gaidar E.V., Kostik M.M., Snegireva L.S., Dubko M.F., Masalova V.V., Serogodskaya E.D., Macijevska A.S., Hynes A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies